secwatch.observer — SEC 8-K summary
======================================

Issuer:     Gossamer Bio, Inc. (GOSS)
CIK:        0001728117
Form:       8-K
Filed at:   2024-03-05T23:59:59+00:00
Accession:  0001728117-24-000018
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Gossamer Bio Q4/FY23 results: first PAH patient dosed in Phase 3 PROSERA, cash $296M into H1 2026
--------------------------------------------------------------------------------

- First PAH patient dosed in registrational Phase 3 PROSERA study; topline results expected Q4 2025.
- Japan PMDA accepted CTN, allowing inclusion of Japanese sites without PK bridging; could support Japanese NDA.
- Cash, equivalents & marketable securities $296.4M at Dec 31, 2023; expected to fund operations into H1 2026.
- Net loss for FY2023: $179.8M ($1.18 per share) vs $229.4M ($2.71) in FY2022.
- R&D expenses FY2023: $135.3M vs $170.9M in FY2022; G&A: $38.5M vs $47.6M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1728117/000172811724000018/0001728117-24-000018-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1728117/000172811724000018/goss-20240305.htm
  HTML page:      https://secwatch.observer/filing/0001728117-24-000018

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer